The study, "Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy," published in The Journal of Experimental Medicine, suggests that inhibiting this molecule may prevent similarly aberrant blood vessels from damaging the vision of not only diabetics, but also premature infants.